Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is responsible for an increased overall disease burden among patients with asthma. Biologics are an establish therapy for severe asthma and its efficacy in patients with co-existent CRSwNP has been a subject of interest.
Aim: To compare the impact of biologic therapy in severe asthma patients with and without CRSwNP.
Materials and methods: Multicenter retrospective study of severe asthma patients under biologic therapy in 2020. We compared 20 patients with CRSwNP with a randomized sample of 34 patients without CRSwNP.
Results: 54 severe asthma patients were included and both groups were homogeneous concerning sex, age, BMI, smoking habits and BMI.
| CRSwNP 20.0(37.0) | Without CRSwNP 34.0(63.0) | p-value Δ | |||
| T/0 | T/6-12M | T/0 | T/6-12M | ||
| ACT SNOT-22 Low dose OCS regime Short-term use OCS+ Asthma exacerbation+ | 10.5[9.0–12.5] 70.3±14.4 7.0(35.0) 3.5[2.0–7.0] 4.0[2.0–12.0] | 22.0[20.0–22.5] 24.1±10.9 3.0(15.0) 0.0[0.0–0.0] 1.0[0.0–1.0] | 9.0[7.0–11.8] - 11.0(32.4) 2.0[2.0–4.0] 3.0[2.0–5.0] | 21.0[19.8–24.0] - 5.0(14.7) 0.0[0.0–1.5] 1.0[0.0–2.0] | 0.419 - 0.822 0.031* 0.078 |
| Eosinophilia | 585.0[300.0-135.0] | 100.0[97.5–232.5] | 350.0[140.0–740.0] | 115.0[65.0–280.0] | 0.139 |
| Pre-bronchodilator FEV1 (%) | 66.9±24,9 | 75.2±17,4 | 58.6±15.8 | 67.1±15.7 | 0.983 |
| Data present as n(%), mean±standard deviation or median[range]. T0–beginning of therapy; T/6-12M–6-12 months after; Δ–variation between T/6-12M and T0. +previous year; *p < 0.05 | |||||
Discussion: Before treatment patients with CRSwNP had more asthma exacerbations with more short-term use of OCS;after biologics, they experience a greater reduction in the total number of prescribed OCS courses acquiring an exacerbation pattern similar to those under biologics without CRSwNP.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3739.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
